TY - JOUR
T1 - Daily phosphodiesterase type 5 inhibitor therapy as rescue for recurrent ischemic priapism after failed androgen ablation
AU - Pierorazio, Phillip M.
AU - Bivalacqua, Trinity J.
AU - Burnett, Arthur L.
PY - 2011/7
Y1 - 2011/7
N2 - The objective of this report is to discuss the potential for normal hormone regulation and application of chronic phosphodiesterase type 5 inhibition for the management of recurrent ischemic priapism. A 64-year-old man presented with refractory priapism treated with antiandrogen therapy. He was transitioned to and well controlled on a regimen of daily phosphodiesterase type 5 inhibitor and every other week antiandrogen therapy. Our treatment of recurrent priapism implicates androgens and both biochemical and neurovascular control mechanisms in the penis.
AB - The objective of this report is to discuss the potential for normal hormone regulation and application of chronic phosphodiesterase type 5 inhibition for the management of recurrent ischemic priapism. A 64-year-old man presented with refractory priapism treated with antiandrogen therapy. He was transitioned to and well controlled on a regimen of daily phosphodiesterase type 5 inhibitor and every other week antiandrogen therapy. Our treatment of recurrent priapism implicates androgens and both biochemical and neurovascular control mechanisms in the penis.
UR - http://www.scopus.com/inward/record.url?scp=80052620374&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80052620374&partnerID=8YFLogxK
U2 - 10.2164/jandrol.110.011890
DO - 10.2164/jandrol.110.011890
M3 - Article
C2 - 21127306
AN - SCOPUS:80052620374
SN - 0196-3635
VL - 32
SP - 371
EP - 374
JO - Journal of andrology
JF - Journal of andrology
IS - 4
ER -